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The  effects  of  isolated  and  associated  cardiovascular  risk
factors  have  been  investigated  since  the  mid-twentieth  cen-
tury,  but  the  relationship  between  the  elements  of  what  is
now  termed  the  metabolic  syndrome  (MetS)  and  cardiovas-
cular  risk  was  paid  little  attention  until  1988,  when  Reaven
described  the  role  of  insulin  resistance  in  human  disease,
which  he  called  syndrome  X.1 This  did  not  include  obesity,
particularly  abdominal  obesity,  which  came  to  be  considered
an  important  component  of  insulin  resistance  syndrome,
now  known  as  MetS,  the  designation  preferred  by  the  Amer-
ican  Association  of  Clinical  Endocrinologists.2
Few  topics  have  received  as  much  attention  in  the  cardio-
vascular  literature  over  the  last  decades  as  risk  prediction.
The  cluster  of  risk  factors  known  as  MetS  is  a  major  public
health  challenge,  due  to  its  high  prevalence  in  the  general
population  and  its  impact  on  the  development  of  cardio-
vascular  disease  (CVD)  and  mortality.3 However,  over  the
last  three  decades  the  debate  about  MetS  has  intensiﬁed,
and  some  of  its  aspects  are  still  generating  a  high  degree  of
interest.  The  existence  of  different  deﬁnitions  of  MetS  ham-
pered  comparisons  between  studies  and  made  it  difﬁcult  to
determine  their  value  in  clinical  practice.  Harmonization  of
the  diagnostic  criteria  of  MetS  was  not  an  easy  process,  but
after  a  new  worldwide  deﬁnition  was  published  in  2005,4
medical  societies  with  a  particular  interest  in  this  condi-
tion  reached  a  consensus  and  developed  a  uniﬁed  deﬁnition,
the  Joint  Interim  Statement  (JIS),  in  2009.5 In  this,  a  singleDOI of original article: https://doi.org/10.1016/j.repc.2018.06.
012
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eplaced  by  ethnicity-speciﬁc  national  or  regional  cutoffs,
nd  a platform  was  established  to  regulate  the  results  of  the
nvestigation.  Thus,  the  threshold  for  waist  circumference
s  still  not  ﬁxed.
MetS  affects  about  25%  of  the  population  but  its  impact
iffers  according  to  age  and  gender,  which  inﬂuence  both
ts  prevalence  and  its  prognostic  signiﬁcance.6 In  the  VAL-
IM  study  in  Portugal,  the  prevalence  of  MetS  (27.5%  overall)
ncreased  with  age  in  both  sexes  up  to  80  years  and  was
igher  in  women  aged  over  50  years.7 The  most  prevalent
omponents  were  increased  blood  pressure  and  abdomi-
al  obesity,  as  in  the  MORGAM  Project6 and  other  studies.
he  prevalence  of  MetS  clearly  increases  with  age  in  both
enders  and  is  higher  in  women.  Cross-sectional  studies
ave  been  crucial  to  determining  its  prevalence;  without
hem,  neither  the  extent  of  the  problem  nor  the  population
ttributable  risk  could  be  determined,  the  latter  depending
n  the  relative  risk  (RR)  or  odds  ratio  of  this  clinical  entity
nd  on  its  prevalence.8
One  question  under  discussion  in  the  assessment  of  the
ardiovascular  risk  of  MetS  is  whether  MetS  is  a  cardiovascu-
ar  risk  factor  beyond  its  individual  components.  The  issue
s  important  because  if  it  is,  MetS  is  a  speciﬁc  entity  that
ust  be  taken  into  account  in  order  to  arrive  at  an  accu-
ate  risk  assessment.  If  the  answer  is  no,  treating  individual
etS  risk  factors  will  be  sufﬁcient.  In  the  literature  there
re  studies  which  appear  to  show  that  MetS  by  itself  has  an
ffect  and  others  in  which  the  estimated  effect  was  close
o  the  null  hypothesis  using  separate  adjusted  multivariate
odels.  The  presence  of  MetS  is  a  good  predictor  of  coro-
ary  heart  disease  (CHD)  and  stroke,  although  not  as  good
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s  the  Framingham  Risk  Score  (FRS),  and  of  type  2  diabetes,
or  which  it  is  better  than  the  FRS.9 In  a  systematic  review
nd  meta-analysis  of  longitudinal  studies  reporting  associa-
ions  between  MetS  and  cardiovascular  events  or  mortality,
etS  had  an  RR  of  cardiovascular  events  and  death  of  1.78
95%  conﬁdence  interval  1.58-2.00).  This  association,  which
emained  after  adjustment  for  traditional  cardiovascular
isk  factors,  was  stronger  in  women.10 However,  this  pub-
ication  prompted  a  letter  to  the  Editor11 with  a  different
onclusion,  based  on  an  analysis  of  three  reference  stud-
es.  In  the  Atherosclerosis  Risk  In  Communities  (ARIC)  study,
cNeill  et  al.12 adjusted  the  risk  associated  with  MetS  for
ts  components,  reporting  a  hazard  ratio  (HR)  of  CHD  of
.91  for  men  and  0.71  for  women,  indicating  that  the  risk
f  CHD  associated  with  the  syndrome  was  not  in  excess  of
he  level  explained  by  the  presence  of  its  individual  com-
onents.  In  the  West  of  Scotland  Coronary  Prevention  Study
WOSCOPS),  Sattar  et  al.13 stated  that  possession  of  MetS
as  not  a  signiﬁcant  predictor  in  the  presence  of  the  effects
f  its  individual  components  when  investigated  in  a  multi-
ariate  model.  Finally,  Schillaci  et  al.14 reported  an  HR  of
.73,  after  adjustment  for  blood  pressure  as  the  only  com-
onent  of  the  MetS.  In  their  reply,  Gami  et  al.  admitted
hat  the  available  data  were  imperfect.11 In  a  study  based
n  36  cohorts  from  the  MORGAM  Project  with  a  12.2-year
ollow-up,  the  CVD  risk  associated  with  MetS  was  higher  in
omen  than  in  men.  Moreover,  in  men,  the  CVD  risk  was
igher  independently  of  age,  whereas  in  women  total  CHD
isk  decreased  signiﬁcantly  and  the  total  stroke  risk  tended
o  increase  (although  not  signiﬁcantly)  with  older  age.  In
omen,  MetS  was  associated  with  higher  RR  for  CHD  events
hat  decreased  with  age,  whereas  RR  for  stroke  tended  to
ncrease.6,15 A  risk  proﬁle  in  which  RR  decreases  with  age
hile  absolute  risk  increases  means  that  the  association
etween  cause  and  possible  effect  is  weak  in  older  indi-
iduals.  The  same  phenomenon  is  also  seen  with  traditional
isk  factors,  such  as  the  relationship  between  smoking  and
HD  mortality,16 or  between  hypertension  and  stroke.17
In  a  comparison  of  the  prognostic  impact  of  different
etS  deﬁnitions  in  predicting  CVD,  the  JIS  deﬁnition  iden-
iﬁed  more  patients  with  MetS,  but  all  deﬁnitions  showed
igher  HRs  in  females  than  in  males.18 Using  information
rom  the  Multi-Ethnic  Study  of  Atherosclerosis  (MESA),  a
opulation-based  cohort  study  of  6776  adults  free  of  clin-
cal  CVD  at  baseline,  latent  class  analysis  showed  a  positive
ssociation  between  MetS  and  incident  CHD  events  in  both
exes.19 A  systematic  review  and  meta-analysis  concluded
hat  patients  with  MetS,  but  without  diabetes,  were  still
t  high  cardiovascular  risk,  with  a  two-fold  increase  in  car-
iovascular  outcomes  and  a  1.5-fold  increase  in  all-cause
ortality,  and  that  studies  were  needed  to  investigate
hether  the  prognostic  signiﬁcance  of  MetS  exceeds  the  risk
ssociated  with  the  sum  of  its  individual  components.3
The  link  between  type  2  diabetes  and  CVD  has  been  rec-
gnized  for  many  years.  It  is  clear  that  individuals  with
iabetes  have  a  greater  likelihood  of  developing  CVD  than
hose  without.20 Diabetes  is  an  independent  risk  factor  for
VD,  even  stronger  in  women,  that  by  itself  increases  risk
or  a  wide  range  of  vascular  diseases  by  about  two-fold
n  average.21 However,  the  risk  depends  on  the  popula-
ion  and  on  the  type  of  cardiovascular  event  (CHD,  stroke
r  peripheral  arterial  disease).21--23 Of  the  conditions  pre-
i
i
t
cE.  Rocha
isposing  to  diabetes,  MetS  is  one  of  the  most  prevalent.
ndeed,  the  association  between  MetS  and  diabetes  is  a
onsequence  of  insulin  resistance  and  strengthens  as  life-
pan  and  exposure  increase.  Hypertension,  dyslipidemia  and
bdominal  obesity  commonly  coexist  with  type  2  diabetes
nd  further  aggravate  the  risk,  which  is  highest  in  people
ith  type  2  diabetes  and  features  of  MetS.23,24 Furthermore,
iabetes  confers  excess  mortality  risk  following  acute  coro-
ary  syndrome  despite  modern  therapies,  highlighting  the
oor  prognosis  of  coronary  patients  with  type  2  diabetes.25
n  order  to  prevent  the  development  of  risk  factors  for  MetS,
ifestyle  changes  are  recommended,  especially  concerning
iet  and  exercise.26 In  the  presence  of  MetS  and  diabetes,
n  addition  to  other  measures  that  may  help  achieve,  main-
ain  or  improve  levels  of  risk  parameters  such  as  lipids,  blood
ressure  and  blood  glucose,  residual  risk  for  CVD  needs  to
e  treated  with  appropriate  drugs,  as  recommended  in  the
uidelines.  The  apparent  inconsistency  in  the  association  of
riglycerides  (TG)  with  CHD  is  not  unexpected,  given  the
omplexities  of  TG  metabolism.27
Knowledge  of  the  likely  prognosis  helps  to  decide  on
he  most  useful  treatment,28 among  other  objectives  (sur-
ival,  case  fatality,  disease  speciﬁc  mortality,  response,
tc.).  In  this  issue  of  the  Journal,  Timóteo  et  al.29 mon-
tored  morbidity  and  mortality  outcomes  during  follow-up
n  a  cohort  study  of  300  individuals  according  to  the  pres-
nce  or  absence  of  MetS  and  CHD.  Of  note  are  the  study’s
haracterization  of  the  occurrence  of  events  under  study  in
ime  using  Cox  regression  analysis  and  its  ability  to  handle
ensored  data  during  a  mean  follow-up  of  6.9  years  with  a
ow  dropout  rate  (1.3%).  Despite  this,  the  study  has  some
imitations,  including  its  approach  to  dealing  with  adjusted
nalyses  of  the  length  of  follow-up  covariate  and  to  testing
otential  interactions  between  independent  variables  and
xcluding  multicollinearity.  Important  explanatory  variables
ere  omitted,  such  as  major  risk  factors  including  the  dura-
ion  of  exposure  to  type  2  diabetes.  Type  2  diabetes  and
etS  are  common  in  patients  with  CHD  or  stroke  and  their
mpact  also  depends  on  duration  of  exposure.  Patients  with
iabetes  and  MetS  are  not  at  the  same  point  in  the  course  of
heir  illness,  since  increased  blood  glucose  is  a  late  and  pos-
ibly  terminal  manifestation  of  insulin  resistance.5 Another
imitation  is  that  the  sample  was  stratiﬁed  into  four  groups,
nd  consequently  the  number  of  some  outcomes  was  low,  so
hat  not  all  differences  between  the  groups  reached  statisti-
al  signiﬁcance.  Moreover,  the  plots  of  survival  against  time
re  shown  in  steps,  but  these  steps  would  be  smaller,  and
he  ﬁgure  would  approximate  a  smooth  curve,  if  the  number
f  patients  had  been  higher.  The  data  do  not  conﬁrm  that
etS,  an  entity  associated  with  increased  cardiovascular  risk
n  people  without  disease,  is  a  marker  of  poor  outcome  in
ick  people  (those  with  CHD  in  secondary  prevention),  but
he  limitations  of  the  approach  do  not  make  this  conclusion
eﬁnitive.
Given  the  available  evidence,  it  is  unequivocal  that  MetS
s  associated  with  increased  cardiovascular  risk  and  even
ore  with  type  2  diabetes,  an  important  health  challenge  in
urope  and  worldwide.  It  must  therefore  be  prevented  and
dentiﬁed  early  to  control  its  components,  the  risk  factors
dentiﬁed  in  the  guidelines.  Research  on  the  risk  of  MetS  in
he  area  of  prognosis,  with  the  purpose  of  predicting  the
ourse  of  CVD  (such  as  CHD)  expressed  as  a  probability  that
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a  particular  event  will  occur  in  the  future,  faces  method-
ological  difﬁculties,  and  no  more  signiﬁcant  contributions
to  clinical  practice  are  expected.  However,  with  regard  to
the  cardiovascular  risk  associated  with  dyslipidemia  there  is
insufﬁcient  evidence,  as  a  direct  causal  link  between  TG  and
CHD  risk  has  still  to  be  demonstrated.  Hypertriglyceridemia
should  not  be  considered  as  a  single  entity  but  rather  mul-
tiple  conditions  (elevated  chylomicrons,  an  increase  in  the
TG  content  of  very  low  density  lipoprotein  (VLDL)  particles
or  an  increase  in  the  total  number  of  VLDL  particles)  that
vary  in  their  CHD  risk,  and  so  new  research  is  needed  to
categorize  phenotypes  of  hypertriglyceridemia.28
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